These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 9658179)

  • 41. Osteoblasts mediate insulin-like growth factor-I and -II stimulation of osteoclast formation and function.
    Hill PA; Reynolds JJ; Meikle MC
    Endocrinology; 1995 Jan; 136(1):124-31. PubMed ID: 7828521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Irisin directly stimulates osteoclastogenesis and bone resorption in vitro and in vivo.
    Estell EG; Le PT; Vegting Y; Kim H; Wrann C; Bouxsein ML; Nagano K; Baron R; Spiegelman BM; Rosen CJ
    Elife; 2020 Aug; 9():. PubMed ID: 32780016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.
    Mohammad KS; Chen CG; Balooch G; Stebbins E; McKenna CR; Davis H; Niewolna M; Peng XH; Nguyen DH; Ionova-Martin SS; Bracey JW; Hogue WR; Wong DH; Ritchie RO; Suva LJ; Derynck R; Guise TA; Alliston T
    PLoS One; 2009; 4(4):e5275. PubMed ID: 19357790
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The osteoclast, bone remodelling and treatment of metabolic bone disease.
    Boyce BF; Rosenberg E; de Papp AE; Duong LT
    Eur J Clin Invest; 2012 Dec; 42(12):1332-41. PubMed ID: 22998735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Friend or Foe? Essential Roles of Osteoclast in Maintaining Skeletal Health.
    Wang H; Yang G; Xiao Y; Luo G; Li G; Li Z
    Biomed Res Int; 2020; 2020():4791786. PubMed ID: 32190665
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
    Liu FL; Chen CL; Lai CC; Lee CC; Chang DM
    Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of transforming growth factor-beta in bone remodeling.
    Bonewald LF; Mundy GR
    Clin Orthop Relat Res; 1990 Jan; (250):261-76. PubMed ID: 2403492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
    Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
    J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rev-erbĪ± Negatively Regulates Osteoclast and Osteoblast Differentiation through p38 MAPK Signaling Pathway.
    Kim K; Kim JH; Kim I; Seong S; Kim N
    Mol Cells; 2020 Jan; 43(1):34-47. PubMed ID: 31896234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preservation of type H vessels and osteoblasts by enhanced preosteoclast platelet-derived growth factor type BB attenuates glucocorticoid-induced osteoporosis in growing mice.
    Yang P; Lv S; Wang Y; Peng Y; Ye Z; Xia Z; Ding G; Cao X; Crane JL
    Bone; 2018 Sep; 114():1-13. PubMed ID: 29800693
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Parathyroid hormone-related protein and bone metastases.
    Guise TA
    Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The regulation of osteoclastic development and function.
    Chambers TJ
    Ciba Found Symp; 1988; 136():92-107. PubMed ID: 3068019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rosmarinic acid exerts an antiosteoporotic effect in the RANKL-induced mouse model of bone loss by promotion of osteoblastic differentiation and inhibition of osteoclastic differentiation.
    Lee JW; Asai M; Jeon SK; Iimura T; Yonezawa T; Cha BY; Woo JT; Yamaguchi A
    Mol Nutr Food Res; 2015 Mar; 59(3):386-400. PubMed ID: 25380345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects of TGF-beta on bone.
    Mundy GR
    Ciba Found Symp; 1991; 157():137-43; discussion 143-51. PubMed ID: 2070682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling.
    Komarova SV; Smith RJ; Dixon SJ; Sims SM; Wahl LM
    Bone; 2003 Aug; 33(2):206-15. PubMed ID: 14499354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Coupling and communication between bone cells].
    Nakashima T
    Clin Calcium; 2014 Jun; 24(6):853-61. PubMed ID: 24870836
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of expression and cell surface binding of members of the transforming growth factor-beta superfamily during retinoic acid-induced osteoblastic differentiation of multipotential mesenchymal cells.
    Gazit D; Ebner R; Kahn AJ; Derynck R
    Mol Endocrinol; 1993 Feb; 7(2):189-98. PubMed ID: 8385738
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extracellular matrix networks in bone remodeling.
    Alford AI; Kozloff KM; Hankenson KD
    Int J Biochem Cell Biol; 2015 Aug; 65():20-31. PubMed ID: 25997875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.